Suven Life Sciences Limited
Clinical trials sponsored by Suven Life Sciences Limited, explained in plain language.
An Indian biopharmaceutical company focused on CNS disorders and contract research services.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
New depression pill shows promise in early trial
Symptom relief CompletedThis study tested a new drug called ropanicant in 41 adults with moderate to severe major depressive disorder. The main goal was to check safety and side effects, while also measuring how well it improved depression symptoms using a standard rating scale. The trial was open-label…
Phase: PHASE2 • Sponsor: Suven Life Sciences Limited • Aim: Symptom relief
Last updated Jun 27, 2026 12:05 UTC
-
New depression pill shows promise in early trial
Symptom relief CompletedThis completed Phase 2b trial tested whether ropanicant, an experimental drug taken twice daily, can reduce symptoms of major depressive disorder. 214 adults with moderate to severe depression received either ropanicant or a placebo for 6 weeks. The main goal was to see if the dr…
Phase: PHASE2 • Sponsor: Suven Life Sciences Limited • Aim: Symptom relief
Last updated Jun 27, 2026 12:04 UTC
-
New drug SUVN-I6107 tested in humans for first time
Knowledge-focused CompletedThis early-stage trial tested the safety and tolerability of a new drug called SUVN-I6107 in 64 healthy adults. Participants received either the drug or a placebo tablet, and researchers monitored for side effects and how the drug moves through the body. The study also looked at …
Phase: PHASE1 • Sponsor: Suven Life Sciences Limited • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:04 UTC